Product
Sham Therapy
1 clinical trial
1 indication
Indication
Central Retinal Vein OcclusionClinical trial
Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein OcclusionStatus: Active (not recruiting), Estimated PCD: 2023-12-01